- £218.75bn
- £236.77bn
- $54.07bn
- 78
- 14
- 98
- 73
REG - AstraZeneca PLC - Lynparza approved in the US for prostate cancer
AnnouncementREG - AstraZeneca PLC - Bevespi Aerosphere approved in China for COPD
AnnouncementREG - AstraZeneca PLC - Enhertu US Breakthrough status for lung cancer
AnnouncementREG - AstraZeneca PLC - Brazikumab rights recovered by AstraZeneca
AnnouncementREG - AstraZeneca PLC - Lynparza gets broader US ovarian cancer approval
AnnouncementREG - AstraZeneca PLC - Enhertu designated gastric cancer BTD
AnnouncementREG - AstraZeneca PLC - Farxiga approved by FDA for heart failure (HFrEF)
AnnouncementREG - AstraZeneca PLC - Total Voting Rights
AnnouncementREG - AstraZeneca PLC - Result of AGM
AnnouncementREG - AstraZeneca PLC - AZN: first-quarter 2020 results
AnnouncementREG - AstraZeneca PLC - Lynparza shows overall survival in prostate cancer
AnnouncementREG - AstraZeneca PLC - Changes to arrangements for AGM
AnnouncementREG - AstraZeneca PLC - Tagrisso adjuvant trial overwhelmingly positive
AnnouncementREG - AstraZeneca PLC - Koselugo (selumetinib) approved in the US for NF1
AnnouncementREG - AstraZeneca PLC - AstraZeneca divestment of Movantik completed
AnnouncementREG - AstraZeneca PLC - Total Voting Rights
AnnouncementREG - AstraZeneca PLC - Director/PDMR Shareholding
AnnouncementREG - AstraZeneca PLC - Imfinzi approved in US for small cell lung cancer
AnnouncementREG - AstraZeneca PLC - Farxiga CKD trial early stop for positive efficacy
Announcement